VMD at a glance
VIEMED HEALTHCARE, INC. (VMD, SEC CIK 1729149) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 20, 2026 and Form 4 insider filings as recently as August 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), VIEMED HEALTHCARE, INC. (VMD) reported revenue of $270.3 million (up 20.5% from FY2024) and net income of $14.9 million. Diluted EPS was $0.37.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding VIEMED HEALTHCARE, INC. (VMD) shares worth $137.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $270.3M
- +20.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $137.7M · +0 vs prior quarter
- Latest 8-K
- Aug 20, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Credit-facility distribution restrictions limiting subsidiary dividend payments under the 2022 Senior Credit Facilities
- Share-repurchase liquidity use: 535,260 shares purchased for $9.65 average price during the quarter
- Remaining repurchase authorization of 1,249,329 shares through March 2027
- No newly triggered regulatory, legal, or compliance risk disclosed this quarter
AI summary of the VMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor deck filed under Regulation FD for use in presentations to investors, analysts and others
- Deck available on Viemed’s investor website and should be read alongside SEC filings and other public announcements
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release and financial supplement available as Exhibits 99.1 and 99.2
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved LTIP expansion to 7,696,717 reserved common shares
- Incentive stock options capped at 1,000,000 shares
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven director nominees reelected, with support ranging from 79.76% to 97.67%
- Sabrina Heltz drew the highest opposition, with 20.24% of votes withheld
AI summaries of VMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VMD
Don't miss the next VMD filing
- Alerts as it files. A push when VMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VMD, by share count.
- Ask anything. An AI agent that reads every VMD filing and answers with sources.
VMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Smokoff Timothy | D | Aug 19, 2026 | 3,757 | $8.94 |
| Heltz Sabrina | M | Aug 19, 2026 | 3,757 | - |
| Smokoff Timothy | M | Aug 19, 2026 | 15,029 | - |
| Smokoff Timothy | M | Aug 19, 2026 | 3,757 | - |
| Kaushal Nitin | M | Aug 19, 2026 | 18,786 | - |
| Heltz Sabrina | M | Aug 19, 2026 | 15,029 | - |
| Heltz Sabrina | M | Aug 19, 2026 | 15,029 | - |
| Heltz Sabrina | D | Aug 19, 2026 | 3,757 | $8.94 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $224.3M | $270.3M |
| Gross Profit | - | $133.2M | $155.5M |
| Operating Income | - | $17.9M | $22.9M |
| Net Income | - | $11.3M | $14.9M |
| Gross Margin | - | 59.4% | 57.5% |
| Op. Margin | - | 8.0% | 8.5% |
| Net Margin | - | 5.0% | 5.5% |
| Balance Sheet | |||
| Total Assets | $154.9M | $177.1M | $199.2M |
| Equity | $113.9M | $131.4M | $141.5M |
| ROE | - | 8.6% | 10.6% |
| Per Share | |||
| EPS | - | $0.28 | $0.37 |
| Cash Flow | |||
| Operating CF | - | $39.1M | $51.9M |
| CapEx | - | $37.8M | $40.0M |
Source: XBRL data in VIEMED HEALTHCARE, INC. (VMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $137.7M |
| Q1 2026 | 25 | $105.4M |
| Q4 2025 | 23 | $84.6M |
| Q3 2025 | 22 | $74.0M |
| Q2 2025 | 22 | $69.8M |
| Q1 2025 | 20 | $36.3M |
| Q4 2024 | 14 | $29.7M |
| Q3 2024 | 9 | $13.0M |
- Citadel Advisors LLC+222.6K (+1898%)
- BlackRock+165.7K (+4%)
- Ameriprise Financial+107.9K (+12%)
- Bank of America Corp+100.5K (+173%)
- AQR Capital Management+91.7K (+81%)
- Goldman Sachs Group−199.1K (-14%)
- Morgan Stanley−24.1K (-7%)
- Renaissance Technologies LLC−16.3K (-4%)
- Mangrove Partners−6.7K (-8%)
- JPMorgan Chase & Co−3.2K (-3%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 160 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 20, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 10-K | Mar 4, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Jan 23, 2026 | - | - |
Related Health Care companies
- AGL · agilon health, inc.Services-Misc Health & Allied Services, NEC
- DVA · DaVitaServices-Misc Health & Allied Services, NEC
- PGNY · Progyny, Inc.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
VMD SEC filings: frequently asked questions
Which institutions hold VMD stock?
As of June 30, 2026, the largest VIEMED HEALTHCARE, INC. (VMD) holders among the 13F filers tracked by SignalX were BlackRock ($54.6 million), Vanguard Capital Management LLC ($15.1 million), Goldman Sachs Group ($13.9 million), Ameriprise Financial ($11.5 million), State Street Corp ($8.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), VIEMED HEALTHCARE, INC. (VMD) reported revenue of $270.3 million (up 20.5% from FY2024) and net income of $14.9 million. Diluted EPS was $0.37. The figures come from the XBRL data in the 10-K.
What did VMD report in its latest 8-K?
VIEMED HEALTHCARE, INC. (VMD) filed an 8-K on August 20, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor deck filed under Regulation FD for use in presentations to investors, analysts and others.
What are the latest VMD SEC filings?
VIEMED HEALTHCARE, INC. (VMD) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 20, 2026 and a Form 4 insider filing on August 19, 2026.
What is VMD's SEC CIK number?
VIEMED HEALTHCARE, INC. (VMD)'s SEC Central Index Key (CIK) is 1729149. EDGAR lists every VMD filing under that number.
Ask anything about VMD
The research agent reads VMD's filings, financials, insider trades and 13F holders, then answers with sources.